GYN: Ovarian, Fallopian, Peritoneal Cancer Clinical Trials

Showing 1-16 of 16 items
1.
  • A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
  • This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. Niraparib is an orally active PARP inhibitor. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI), European Quality of Life scale, 5-Dimensions (EQ-5D), and a neuropathy questionnaire. Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values. The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (PFS).
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
2.
  • Tivozanib As Maintenance Therapy In GYN
  • This research study is evaluating a drug called tivozanib as a possible treatment for ovarian, fallopian tube or primary peritoneal cancer. Angiogenesis is the formation of new blood vessels. Tumors need blood vessels to grow and spread. Tivozanib is an anti-angiogenesis medicine that fights cancer by cutting off a tumor's blood supply so that it does not get the blood and nutrients it needs to grow. In this research study, the Investigators are looking to see whether tivozanib works as a maintenance therapy for ovarian, fallopian tube or primary peritoneal carcinoma in participants who have achieved a complete response following chemotherapy. Maintenance therapy is given after a disease has responded to previous treatment. It is given to help prevent the spread or recurrence of the tumor.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
3.
  • CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
  • This research study is a Phase II clinical trial. In addition to studying safety, Phase II clinical trials test if the investigational drug is effective and whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA (the U.S. Food and Drug Administration) has not yet approved CRLX101 for your type of cancer. Camptothecin is a chemical extracted from plants that is the basis for the standard FDA-approved chemotherapy drugs irinotecan and topotecan. Camptothecin works by interfering with the way cells divide and multiply. The investigational drug CRLX101 is a formulation of camptothecin and a large molecule (nanoparticle)that appears to allow more of the camptothecin to get into tumors and stay in tumors. The persistence of the CRLX101 in the tumor may increase the probability that the tumor cells will be damaged. CRLX101 has been well tolerated in the laboratory and in participants with different kinds of cancer. Bevacizumab (Avastin) is a VEGF inhibitor which has activity in many kinds of cancer. Bevacizumab has been successfully combined with many chemotherapy partners. It has been hypothesized that the combination of bevacizumab with CRLX101 might have unique clinical activity in combination in the treatment of this disease due to the simultaneous inhibition of distinct steps along the HIF → (CAIX) → VEGF → VEGFR2 pathway. Specifically, it is hypothesized that CRLX101-mediated inhibition of HIF-1α carries with it the potential to interrupt hypoxia and HIF-1α-associated resistance to VEGFR inhibitors. It is hoped that this combination will work to treat your type of cancer.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
4.
5.
  • Phase II of Carbo/Pralatrexate in Rec. Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
  • Pralatrexate is a type of antifolate drug which means is restrains the production of folic acid in the body. Folic acids are used by tumors to increase tumor cell growth and division. It is believed that reducing folic acid will hinder the rapid division of tumor cells, their growth and production. Carboplatin is an FDA approved chemotherapy drug for ovarian, fallopian tube and primary peritoneal cancer. Some antifolate drugs are used with other chemotherapy drugs to enhance cancer-fighting characteristics. It is believed that the study drug pralatrexate may improve the anti-tumor effect of carboplatin. In this research study we are looking for the highest dose of pralatrexate that can be given safely in combination with carboplatin.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
6.
  • VB-111+Paclitaxel for Recurrent Mullerian Cancer
  • This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved VB-111, or the combination of VB-111 with paclitaxel for use in patients, including people with your type of cancer. VB-111 is designed to kill cancer cells in the body by "cutting off" the blood flow to cancer cells and/or tumors. The process of "cutting off" the blood flow to cancer cells and/or tumors is known as anti-angiogenesis and has been shown to help prevent tumor growth. VB-111 is both a vascular disrupting (blocking blood vessels) and anti-angiogenic (preventing new blood vessel growth) agent. It is different to normal chemotherapy as it is made from an adenovirus (Cold virus) carrying a human gene that kills cell lining blood vessels (Endothelial cells). This virus is a 'non-replicating' virus, meaning it cannot grow in the body. Paclitaxel is a chemotherapy drug which is FDA approved for use in your type of cancer. In this research study, we are looking for the highest dose of VB-111 that can be given safely in combination with paclitaxel to patients with platinum-resistant ovarian cancer.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Endometrial/Uterine Cancer
  • Status: Recruiting
7.
  • Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, Peritoneal Cancer, or Triple-Negative Breast Cancer
  • There are two parts to this study. The first part of this research study has the purpose of determining the safety of the combination of the two drugs cediranib and olaparib and the highest doses of these two drugs that can be given in combination to people safely. Cediranib is a drug that may help keep cancer cells from growing by affecting their blood supply. Olaparib is a drug that may stop cancer cells from growing abnormally. These drugs have been used in other research studies in ovarian and breast cancer, and information from those other research studies suggest that these may help to keep cancer from growing in this research study. This study is now entering the second part of the study, where we are comparing the effects of the combination of olaparib and cediranib to that of olaparib only in women with certain types of recurrent ovarian, fallopian tube, or primary peritoneal cancers.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
8.
9.
10.
  • Phase I of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
  • This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs. Phase I studies also try to define the appropriate dose of the investigational combination to use for further studies. "Investigational" means that the combination of these drugs is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved either of these drugs nor the combination of being tested for use in patients, including people with your type of cancer. BKM120 and olaparib are drugs that may stop cancer cells from growing abnormally. These drugs when combined in laboratory experiments with animals, have demonstrated anti-cancer activity. Information from these other research studies suggests that both of these agents BKM120 and olaparib, may help to shrink tumor cells in the types of cancers being studied in this research study. In this research study, the investigators are looking for the highest dose that can be given safely and also to see if the combination of BKM120 and olaparib is effective in treating your type of cancer.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
11.
12.
13.
14.
15.
  • Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
  • This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant. In the initial dose-escalation stage of the study, adult female subjects will receive conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to determine the MTD of birinapant when administered with a fixed dose of conatumumab. In safety expansion stage, adult female subjects will receive conatumumab in combination with birinapant at the MTD of the combination.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
16.
Showing 1-16 of 16 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms